Bronstein, Gewirtz & Grossman, LLC Encourages GSK plc (GSK) Stockholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / July 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GSK plc ("GSK" or "the Company") . Investors who purchased GSK securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GSK.Investigation DetailsOn July 17, 2025, GSK issued a press release announcing "that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations." On this news, GSK's American Depositary Receipt ("ADR") price fell $1.81 per share, or 4.73%, to close at $36.47 per share on July 17, 2025.What's Next?If you are aware of any facts relating to this investigation or purchased GSK securities, you can assist this investigation by visiting the firm's site: bgandg.com/GSK. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660There is No Cost to YouWe represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.Why Bronstein, Gewirtz & GrossmanBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.Follow us for updates on LinkedIn, X, Facebook, or Instagram.Attorney advertising. Prior results do not guarantee similar outcomes.ContactBronstein, Gewirtz & Grossman, LLCPeretz Bronstein or Nathan Miller332-239-2660 | info@bgandg.comSOURCE: Bronstein, Gewirtz & Grossman, LLCView the original press release on ACCESS Newswire